HQL-79 – 5 mg

Brand:
Cayman
CAS:
162641-16-9
Storage:
-20
UN-No:
Non-Hazardous - /

HQL-79 is a selective inhibitor of hematopoietic prostaglandin D (PGD) synthase. Structurally, it is a synthetic tetrazole compound originally prepared as a possible antihistamine.{11338} Subsequent evaluation in models of allergy and asthma demonstrates the HQL-79 is orally available, and inhibits the synthesis of PGD2 (Item No. 12010).{11337} HQL-79 is thus a likely lead compound for the preparation of potent, selective hematopoietic PGD synthase inhibitors.  

 

Available on backorder

SKU: 10134 - 5 mg Category:

Description

HQL-79 is a selective inhibitor of hematopoietic PGD synthase. Structurally, it is a synthetic tetrazole compound originally prepared as a possible antihistamine.{11338} Subsequent evaluation in models of allergy and asthma demonstrates the HQL-79 is orally available, and inhibits the synthesis of PGD2 (Item No. 12010).{11337} HQL-79 is thus a likely lead compound for the preparation of potent, selective hematopoietic PGD synthase inhibitors.


Formal name: 4-(diphenylmethoxy)-1-[3-(1H-tetrazol-5-yl)propyl]-piperidine

Synonyms: 

Molecular weight: 377.5

CAS: 162641-16-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Immunology & Inflammation|Allergy||Research Area|Immunology & Inflammation|Inflammatory Lipid Mediators|Prostaglandins||Research Area|Immunology & Inflammation|Pulmonary Diseases|Asthma